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Criteria to rule out SARS-CoV-2

Abstract
Objectives
Accurate and reliable criteria to rapidly estimate the probability of infection with the novel
coronavirus-2 that causes the severe acute respiratory syndrome (SARS-CoV-2) and associated disease (COVID-19) remain an urgent unmet need, especially in emergency care.
The objective was to derive and validate a clinical prediction score for SARS-CoV-2 infection
that uses simple criteria widely available at the point of care.

Methods
Data came from the registry data from the national REgistry of suspected COVID-19 in
EmeRgency care (RECOVER network) comprising 116 hospitals from 25 states in the US.
Clinical variables and 30-day outcomes were abstracted from medical records of 19,850
emergency department (ED) patients tested for SARS-CoV-2. The criterion standard for
diagnosis of SARS-CoV-2 required a positive molecular test from a swabbed sample or positive antibody testing within 30 days. The prediction score was derived from a 50% random
sample (n = 9,925) using unadjusted analysis of 107 candidate variables as a screening
step, followed by stepwise forward logistic regression on 72 variables.

Results
Multivariable regression yielded a 13-variable score, which was simplified to a 13-point
score: +1 point each for age>50 years, measured temperature>37.5˚C, oxygen saturation<95%, Black race, Hispanic or Latino ethnicity, household contact with known or suspected COVID-19, patient reported history of dry cough, anosmia/dysgeusia, myalgias or
fever; and -1 point each for White race, no direct contact with infected person, or smoking.
In the validation sample (n = 9,975), the probability from logistic regression score produced
an area under the receiver operating characteristic curve of 0.80 (95% CI: 0.79–0.81), and
this level of accuracy was retained across patients enrolled from the early spring to summer
of 2020. In the simplified score, a score of zero produced a sensitivity of 95.6% (94.8–
96.3%), specificity of 20.0% (19.0–21.0%), negative likelihood ratio of 0.22 (0.19–0.26).
Increasing points on the simplified score predicted higher probability of infection (e.g., >75%
probability with +5 or more points).

Conclusion
Criteria that are available at the point of care can accurately predict the probability of SARSCoV-2 infection. These criteria could assist with decisions about isolation and testing at high
throughput checkpoints.

Introduction
The ability to rapidly estimate the probability of infection with the novel coronovirus-2 that
causes severe acute respiratory syndrome (SARS-CoV-2) remains a formidable problem. The
protean clinical picture of SARS-CoV-2 infection confounds its prediction. For example, the
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disease syndrome that SARS-Cov-2 produces—recognized as COVID-19—can manifest a
wide range of nasopharyngeal, respiratory, and gastrointestinal symptoms, and a substantial
minority of patients who carry SARS-CoV-2 manifest no symptoms at the time of testing [1,2].
Asymptomatic patients can manifest nasopharyngeal viral loads, and shedding capacity similar
to symptomatic, infected persons [3,4]. Factors limiting our current knowledge include the
lack of systematically collected data from a large, unbiased, geographically diverse samples of
patients, and problems associated with limited availability of molecular diagnostic tests and
assays, long turnaround time and low diagnostic accuracy [3,5–7]. The need for rapid exclusion without molecular testing arises daily in health care clinics, outpatient treatment facilities,
at the point of intake for homeless shelters, judicial centers for incarceration, and extended
care facilities. This need is particularly urgent in the emergency department (ED), which represents the largest interface between the general public and unscheduled medical care. In 2016,
the >5000 US EDs had approximately 145 million patients [8]. Additionally, because the ED
interconnects with both outpatient and inpatient medical care, the critical question of SARSCoV-2 infection status affects decisions to admit or discharge the patient, return to work, need
for home isolation, and the location of hospital admission. These questions become more complicated for patients without access to basic medical care, and those experiencing serious mental illness, substance use disorders, and homelessness.
To address these needs, the authors created the REgistry of suspected COVID-19 in EmeRgency care (RECOVER), a national network to capture data from patients tested for SARSCoV-2 and evaluated in the ED [9]. This report addresses the primary goal of the initial network-wide registry, which was to create a quantitative pretest probability scoring system (putatively named the COVID-19 Rule Out Criteria score [CORC score])to predict the probability
of a SARS-CoV-2 test, with special attention to identify those at very low probability of infection. The intent of the score was to function similarly to the Wells pretest probability scoring
criteria and Pulmonary Embolism Rule out Criteria (PERC rule) for acute pulmonary embolism, respectively, except the diagnostic target was SARS-CoV-2 [10,11].

Materials and methods
The RECOVERY network has resulted from the collaboration of 45 emergency medicine clinician-investigators from unique medical centers in 27 US states. Most of the 45 medical centers
participating are the flagships of hospital networks that include community and academic centers. Information about these sites, and the methods of the initial registry, are available elsewhere [9]. The primary objective of the registry was to obtain a large sample of ED patients
with suspected SARS-CoV-2 and who had a molecular test performed in the ED as part of
their usual care. The design, collection, recording and analysis of data for this report were conducted in accordance with the transparency in reporting of a multivariable prediction model
for individual diagnosis and prognosis (TRIPOD) criteria [12]. The RECOVER registry protocol was reviewed by the institutional review boards (IRBs) at all sites; 42 IRBs provided an
exemption from human subjects designation, whereas three IRBs provided approval with
waiver of informed consent. All data were anonymized prior to analysis.
Briefly, eligibility for enrollment required that a molecular diagnostic test was ordered and
performed in the ED setting with suspicion of possible SARS-CoV-2 infection, or COVID-19
disease [9]. Patients could only be enrolled once. Otherwise, there were no age or symptombased exclusions; however, the guidance was provided to exclude patients where the test was
clearly done for automated, administrative purposes in the absence of any clinical suspicion
for infection. One example for exclusion was patients without suspected infection but who had
swab testing performed in the ED done only to comply with a hospital screening policy for

PLOS ONE | https://doi.org/10.1371/journal.pone.0248438 March 10, 2021

3 / 15

PLOS ONE

Criteria to rule out SARS-CoV-2

admissions or pre-operative testing. All sites were contracted to abstract charts from at least
500 patients.
Data were collected from the electronic medical record, using a combination of electronic
download for routinely collected, coded variables (e.g., age, vital signs and laboratory values),
supplemented by chart review by research personnel, using methods previously described [9].
Each REDcap data form included 204 questions resulting in 360 answers, because many questions allowed multiple answers. Data were archived in the REDCap1 system, with electronic
programming to ensure completion of mandatory fields and sensible ranges for parametric
data. Training of data abstractors was done via teleconference with the principal investigator
(JAK) and program manager (KLP), supplemented by an extensive guidance document and
field notes present in the REDCap1 system, visible to the person doing enrollment. This analysis was pre-planned as the first manuscript from the RECOVER network.
To generate a comprehensive pool of independent variables for a quantitative pretest probability model, as well as harmonization with other data, among the 204 questions, we recorded
28 symptoms, including all symptoms from the Clinical Characterization Protocol from the
World Health Organization-supported International Severe Acute Respiratory and Emerging
Infection Consortium (ISARIC) [13]. The REDCap form also recorded 14 contact exposure
risks, ranging from no known exposure, to constant exposure to a household contact with
COVID-19. We anticipated that many patients would have multiple ED visits prior to testing,
especially for atypical presentations, and the goal was to collect patient data from the earliest
medical presentation. Accordingly, the symptoms and contact risks, together with the vital
signs (body temperature, heart rate, respiratory rate, systolic and diastolic blood pressure and
pulse oximetry reading) were recorded from the first ED visit within the previous 14 days (the
“index visit”). The form also documented presence or absence of 18 home medications and 39
questions about past medical history. Outcomes, including results of repeated molecular testing, or antibody testing for SARs-CoV-2 were recorded up to 30 days after the date of the
SARS-CoV-2 test that qualified the patient for enrollment.
The criterion standard for disease positive was evidence of SARs-CoV-2 infection, from
either a positive molecular diagnostic test from a swab sample (usually from the nasopharynx),
or a positive serological IgM or IgG antibody, documented within 30 days of enrollment. The
criterion standard for disease negative required that patients have no positive molecular or
serological test for SARS-CoV-2 or clinical diagnosis of COVID-19 within 30 days.

Model development
After upload, each REDCap form was inspected centrally for completeness and sensibility of
data, resulting in verification queries. For example, if a patient had none of 28 symptoms, the
site investigator was asked to double-check the medical record. Uploaded records were considered eligible for analysis after resolution of queries coupled with electronic verification by
the data abstractor and site investigator that each uploaded record was a true and complete
reflection of data in the medical record. The a priori plan for model development called for a
classical approach of screening candidate variables with unadjusted analyses, followed by multivariable logistic regression analysis with conversion into either a scoring system or a set of
criteria. The REDCap data collection form was produced in March 2020, when the phenotype
of patients with SARs-CoV-2 infection was incompletely understood. Thus, the plan was an
agnostic approach: to screen all potential variables for discriminative value, including method
and day of arrival to the ED, patient demographics, symptoms, vital signs, contact risks, habits,
medications and past medical history. As previously described, we estimated a minimum sample size of 20,000 to allow derivation and validation on approximately 10,000 patients in each
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step, assuming a 30% criterion standard positive rate and a greater than 10:1 ratio of outcomes
to variables, recognizing this as a minimum criterion [9,12,14].
To derive the CORC score, we first extracted a 50% random sample, and, for statistical testing, used the criterion standard result as the dependent variable. Per protocol, categorical data
that were not charted were considered absent, but missing continuous data (>0.1%, age, vital
signs, and body mass index) were analyzed for monotonicity and replaced using multiple
imputations method in SPSS1 (IBM Corp. Released 2020. IBM SPSS Statistics for Windows,
Version 27.0. Armonk, NY: IBM Corp). The mean values from five iterations were used. Bivariate data were compared between test + and test—using the Chi-Square statistic and means
from parametric variables (e.g., age) were compared using unpaired t-test. Variables with
P<0.05 were entered into logistic regression equation, initially leaving parametric data as continuous (to create the probability from logistic regression), and variables selected for score
development using an empirical stepwise forward approach using the likelihood ratio
approach. “The model was terminated when the change Akaiki information criterion
(AIC = 2k-2ln(L) where k = number of variables and L = maximum likelihood) reached its
nadir. Model fitness was assessed with the Hosmer-Lemeshow test.
To produce the actual CORC score (a simplified version of the logistic regression equation),
we dichotomized continuous data at the midpoint of the difference in means between patients
with and without SARS-CoV-2 infection. To test for validity, the probability from logistic
regression was computed by solving for probability (P) from the logistic regression equation
(obtained from the antilog of the logistic regression equation yielding P = [1+exp(-Scoefficients+intercept)]-1); the net positive points for the CORC score were calculated for each of
the remaining 50% of patients in the registry, who were independent of the derivation population. Diagnostic accuracy of the probabilityfrom logistic regression and CORC score were
assessed in the validation with receiver operating characteristic curve and diagnostic indexes
from contingency table analysis. Data were analyzed with SPSS1 software with the Complex
Sampling and Testing module.

Results
Data for this analysis were downloaded from the registry on December 3, 2020. The download
included 20,060 complete records collected per protocol from 41 hospital systems representing
116 unique hospitals from 25 states. Eligible records came from patients tested for SARS-CoV2 from the first week of February, until the fifth week of October, 2020. After exclusion of 210
records marked by the sites as screen fails (from a later discovered exclusion criterion), 19,850
records were left for analysis. Multiple imputation successfully replaced all missing parametric
values, including body mass index as the most frequently missing value (in 25%), followed by
respiratory rate (1.4%). For age, blood pressure, and pulse oximetry, values were missing in
less than 1% of the samples. Each record was then assigned a random number drawn from 1 to
19,850, and re-sequenced, and the first and second halves were used to derive and test the
probabilityfrom logistic regression, respectively. Table 1 shows the clinical characteristics of
the sample, divided into the derivation and validation groups, and indicates that random sampling produced two comparable groups. Compared with US Census Bureau data from 2019,
the median age of this ED sample is older by approximately 12 years, and has approximately a
13% higher representation of persons identifying as Black (and lower percentage of persons
identifying as White), but a similar distribution of biological sex and Hispanic or Latino ethnicity [15]. Table 1 conveys findings that are important to developing accurate pretest probability criteria using criteria available at the bedside. First, the pooled prevalence of infection
among those tested was 34%, which is relatively high for producing exclusionary criteria.
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Table 1. Clinical features of the derivation and validation samples.
Derivation (n = 9925)
mean

Validation (N = 9925)

SD

mean

SD

Age (years)

50

20.6

51

Number of symptoms at presentation

4.5

1.9

4.6

20.4
1.9

Duration of symptoms (days)

5.4

9.7

5.5

10.1

Heart rate (beats/min)

94.7

21.6

94.7

21.3

Respiratory rate (breaths/min)

20.1

5.5

20.0

5.4

Pulse oximetry at triage (%)

96

6.0

96

6.5

Lowest pulse oximetry reading (%)

94

7.3

94

7.6

Temperature (Celsius)

37.1

1.1

37.1

1.2

Systolic blood pressure (mm Hg)

134

25.6

134

25.3
16.4

Diastolic blood pressure (mm Hg)

80

16.6

80

Body mass index (Kg/m^2)

30

10.1

30

9.8

Days between SARS-CoV-2 test order and result

1.4

2.3

1.5

2.4

n
Age<18 years

% of group
425.0

Female sex

n
4%

5201

% of group
444.0

52%

4%
5226

53%

Asian race

289

3%

252

3%

Black race

2630

26%

2686

27%

White race

5301

53%

5180

52%

Hispanic or Latino ethnicity

1748

18%

1729

17%

334

3%

325

3%

Obese

2501

25%

2587

26%

Diabetes mellitus

2262

23%

2317

23%

Hyperlipidemia

2782

28%

2808

28%

Homeless

Hypertension

4157

42%

4229

43%

Active cancer

1214

12%

1217

12%

Prior organ transplantation

167

2%

178

2%

Atrial fibrillation

779

8%

803

8%

Ischemic heart disease

950

10%

996

10%

Heart failure

968

10%

1007

10%

Chronic obstructive pulmonary disease

1027

10%

1019

10%

Asthma

1623

16%

1558

16%

Prior venous thromboembolism
Current smoker
No symptoms
SARS-CoV-2 infection

598

6%

583

6%

1792

18%

1770

18%

20

0%

13

0%

3443

35%

3422

34%
45%

Influenza testing done�

4514

45%

4506

Other viral testing†

3873

39%

3839

39%

Chest radiograph done

7499

76%

7493

75%

Laboratory analysis of blood specimen

7600

77%

7624

77%

�

Influenza A, B or both positive = 279/90020 (3% positive rate)

†

One or more other viruses detected = 1122/7712 (15% positive rate).

https://doi.org/10.1371/journal.pone.0248438.t001

Second, the mean turn-around-time for SARS-CoV-2 testing was greater than one day,
although the median time was 0.5 days (interquartile range 0–1.0). Third, approximately 5%
of the sample had none of the 28 recorded symptoms at presentation, but still had clinical
suspicion that led to testing. Fourth, approximately one-quarter of all patients had no chest
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Table 2. Logistic regression results of the selected model (the probability from logistic regression).
Coefficient

Odds ratio

95% CI
Lower

Upper

Black race

0.88

2.40

2.04

2.82

White race

-0.42

0.66

0.57

0.76

Hispanic or Latino ethnicity

1.34

3.81

3.28

4.42

Age in years

0.02

1.02

1.02

1.02

Symptom: Loss of sense of taste or smell

1.93

6.89

5.22

9.11

Symptom: Non-productive cough

0.43

1.54

1.39

1.70

Symptom: Fever

0.44

1.55

1.39

1.72

Symptom: Muscle aches

0.48

1.61

1.43

1.81

-0.45

0.64

0.57

0.71

1.68

5.36

4.42

6.51

Pulse oximetry at triage

-0.04

0.96

0.95

0.97

Temperature in Celsius

0.44

1.55

1.46

1.65

-0.81

0.45

0.39

0.51

Exposure to COVID-19: None known
Exposure to COVID-19: Household contact with known or suspected infection

Current smoker
Intercept

-14.78

N/A

Model analysis: Hosmer Lemeshow P = 0.526, McFadden’s pseudo R2 = 0.22, C statistic = 0.80.
https://doi.org/10.1371/journal.pone.0248438.t002

radiograph performed and almost one-quarter had no laboratory analysis of a blood specimen.
Additional data of relevance include the fact that 1,915 patients (10%) had visited the ED
within the previous 14 days prior to testing for SARS-CoV-2, but records documented clinical
suspicion for COVID-19 in only 367 (19%) of these visits.
Of 107 candidate variables shown in S1 Table, 72 had P<0.05 by univariate statistical analysis (Chi-Square for bivariate data and unpaired t-test for continuous data), comparing data
from patients with positive SARS-CoV-2 testing versus patients with negative test. These 72
variables were subsequently evaluated by stepwise forward multivariable logistic regression
using the likelihood ratio method. After exclusion of 42 variables that were not significant, the
procedure was repeated with 30 variables. The model selected for the probability from logistic
regression was from step 13 (13 variables) based upon consideration of the need to limit number of variables for practical use with maintenance of model fitness by keeping the HosmerLemeshow P value >0.10. These 13 variables were then examined by a single-step logistic
regression to produce Table 2. This model produced a C-statistic (area under the receiver
operating characteristic curve) of 0.80 (0.79–0.81). When the equation solved for probability,
at a cutoff of 0.1 this yielded sensitivity of 97% and specificity of 20% in the derivation population. Table 3 shows the simplification of the probability from logistic regression into the 13
component CORC score, which included the dichotomization of age, temperature and the
pulse oximetry reading obtained at the time of triage in the ED. With the exception of the
anosmia/dysgeusia variable, the use of whole digits (-1 or +1, score range -3 to +10) proportionately reflect the sign and rounded magnitude of the beta coefficients and intercept
obtained from repeated logistic regression with age, pulse oximetry and temperature converted
to dichotomous variables with cutoffs at 50 years, 94.5% and 37.5˚C respectively. With 0 or
fewer points considered a test negative CORC score result, a negative CORC score produced
diagnostic sensitivity of 96% and specificity of 21% in the derivation population.
When applied to the other half of the sample (validation group, n = 9925), the probability
from logistic regression and CORC score performed similarly. The probability from logistic
regression had an area under the receiver operating characteristic of 0.80 (95% CI, 0.79 to
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Table 3. The COVID-19 rule out criteria (CORC score).
Component
Black race

Points
+1

White race

-1

Hispanic or Latino ethnicity

+1

Age >50 years

+1

Symptom: Loss of sense of taste or smell

+1

Symptom: Non-productive cough

+1

Symptom: Fever

+1

Symptom: Muscle aches

+1

Exposure to COVID-19: None known

-1

Exposure to COVID-19: Household contact with known or suspected infection

+1

Pulse oximetry at triage <95%

+1

Temperature in Celsius >37.5

+1

Current smoker

-1

https://doi.org/10.1371/journal.pone.0248438.t003

0.81), and when solved for probability (P), if P<0.1, the diagnostic sensitivity was 96.8% (96.1
to 97.3%) and the specificity was 20.1% (19.1 to 21.1%), yielding a posterior probability of
7.8% (6.5 to 9.8%). The accuracy of the probability from logistic regression in the validation
dataset was maintained across the month of diagnosis. For the 8,444 patients evaluated early in
the US pandemic (February to May 2020) the area under the receiver operating characteristic
curve for the probability from logistic regression was 0.80 (0.79 to 0.81), compared with 0.81
(0.79 to 0.84) for 1,481 patients evaluated from June 2020 onward. The probability from logistic regression area under the receiver operating characteristic curve was decreased in patients
with zero symptoms (0.73, 0.69 to 0.77).
In the validation set, the CORC score negative (0 or fewer points from Table 3) produced
sensitivity of 95.6% (94.8 to 96.3%), specificity of 20.0% (19.0 to 21.0%), likelihood ratio negative of 0.22 (0.19 to 0.26) and a posterior probability of 10.4% (8.9 to 12.1%). The probability
of infection increases with the number of positive points from the CORC score. This stepwise,
positive concordance is shown in Fig 1, which plots the posterior probability of positive
SARS-CoV-2 testing as a function of the number of points from the CORC score from the validation population. The probability of SARs-CoV-2 infection is >75% in a patient with +5 or
more points from the CORC score.
Table 4 shows the standard diagnostic contingency table (also referred to as a confusion
matrix) using a CORC score >0 as the definition of a positive test result with associated calculations of precision, recall and F1 index. Fig 2 shows the plots of the precision-recall curve and
receiver operating characteristic curve with their AUC data. The CORC score had a slightly
lower area under the curve (0.75, 0.74–0.76) than the probability from logistic regression (0.80,
0.79–0.81).
Given the concern about low diagnostic sensitivity for molecular testing on swab samples, a
relevant question is how the CORC score performed among patients with an initially negative
swab test who had subsequent evidence of SARS-CoV-2 infection within 30 days. From the
entire sample (both derivation and validation), the initial swab that qualified the patient for
enrollment was negative in 13,159 patients. Of these, 174 (1.1%) subsequently had evidence of
SARs-CoV-2 from either a repeated nasopharyngeal swab or positive antibody testing done
within 30 days. Among these 174 patients who had a possibly false negative molecular test
done on a swab sample, the CORC score was >0 in 87%.
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Fig 1. The CORC score by number of points. The probability of SARS-CoV-2 infection increased according to
number of points from the CORC score.
https://doi.org/10.1371/journal.pone.0248438.g001

Table 4. Contingency table (confusion matrix) for the CORC score.
CORC>0

CORC< = 0

SARS-CoV-2+

3271

151

SARS-CoV-2-

5201

1302

Precision = 3271/(3272+5201) = 0.39.
Recall = 3271/(3271+151) = 0.96.
F1 = (0.39� 0.96)/(0.39+0.96) = 0.55.
Abbreviations: CORC-COVID-19 Rule-Out Criteria.
https://doi.org/10.1371/journal.pone.0248438.t004

Discussion
This work addresses the urgent need for criteria to rapidly, easily, and accurately estimate the
probability of SARs-CoV-2 infection. Using registry data from the RECOVER Network, which
was specifically created to address this knowledge gap, we found that 13 variables—11 of
which were obtained from verbal interview, together with one data point each from a thermometer and a pulse oximeter—can accurately predict the probability of SARS-CoV-2 infection if entered into a logistic regression equation and solved for probability (the probability
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Fig 2. Diagnostic performance of the CORC score. The plot in the top panel shows the precision-recall curve and the
plot in the lower panel shows the receiver operating characteristic curve for the COVID-19 Rule Out Criteria (CORC)
score.
https://doi.org/10.1371/journal.pone.0248438.g002
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from logistic regression) [9]. A simpler version comprising 13 binary variables, scored with
negative or positive point values (the CORC score, shown in Table 3) provides similar accuracy. To our knowledge, this is the first prediction rule (or score) for SARS-CoV-2 infection
that does not require laboratory or radiographic data which makes this model very useful in
high throughput settings, such as triage areas of emergency departments and also in non hospital settings such as homeless encampments and street medicine.
The probability from logistic regression was derived from a large patient pool enrolled
from 27 states with demographics reflective of the overall US population. The overall utility
and durability of the probability from logistic regression is suggested by the area under the
receiver operating characteristic curve of 0.80 in both the derivation and validation samples,
and that this level of accuracy was retained in patients tested either earlier or later in the first
year of the US SARS-CoV-2 pandemic. A negative CORC score (0 or fewer points) had 95.6%
sensitivity and 20.0% specificity in the validation sample, providing a likelihood ratio negative
of 0.22 (95% CI 0.19 to 0.26). Moreover, the CORC score was positive (>0 points) in the 87%
of patients with an initially negative and subsequently positive molecular test for SARS-CoV-2
done on a swab sample from the nasopharynx. For the goal of predicting high risk of infection,
patients in the validation sample with a +5 or more points from the CORC score had a >75%
probability of a positive test. Thus, assuming the expected prevalence of SARS-CoV-2 infection
is below 10%, the estimated likelihood ratio negative of 0.22, a CORC score of zero or less
would allow a very low posterior probability (e.g., <2.0%) and thus may obviate the need for
molecular testing or isolation in a negative pressure room in the ED setting. On the other
hand, a CORC score �5 should be considered predictive of high risk, suggesting the need for
molecular testing, and possibly repeated testing if the first test is negative [16].
In terms of methodological strength, the large, diverse, and representative patient sample of
patients tested for SARS-CoV-2 has a low risk of sampling bias, which has hampered previous
prediction rules for COVID-19 [17]. The practical benefit of the CORC criteria is the lack of
requirement for radiological or laboratory data, which were not ordered in the usual care of
over a quarter of patients in this sample and are not available in many settings where risk
assessment for probability of SARS-CoV-2 infection is critical to decision-making. These findings suggest that the CORC score, if validated in prospective work, can assist with decisions
about need for formal diagnostic testing and isolation procedures for persons passing through
high throughput settings including the triage area of some emergency departments and medical clinics, and at the point of entry for homeless shelters, industry, correctional facilities, and
extended care facilities. In the home setting thermometers are common and in some protocols
pulse oximetry has been used to monitor outpatients with known COVID-19 [18]. Thus, in
concept, the CORC score could be an adjunctive measure to assess the probability of SARSCoV-2 among household contacts of persons known to be infected. After prospective validation, the CORC score may also help reduce low-value repeated molecular testing after initial
infection, that could produce false positive results.
The data for the probability from logistic regression and CORC score were obtained retrospectively using rigorous methods to ensure high value variables, and unique, relevant circumstantial data. In contrast to many recent reports using clinical informatics, the level of detail
for the data from this study required manual evaluation of medical records by research personnel. For example, manual review was required to ensure that the symptoms recorded represented those that the patient manifested on the first contact with the healthcare system while
infected with SARs-CoV-2—which was the case for 1,915, or 10% of the cohort. The probability from logistic regression was a required step to create the simpler CORC score. The more
formal probability from logistic regression is calculated by exponentiating the logistic regression equation and solving for probability, a task easily performed using an online or internet-
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based calculator. However, recognizing prior literature on the real-world behavior of physicians, we believe a simpler scoring system comprising positive or negative whole single digits
will enhance dissemination and adoption [19,20].
The variables retained by the selection process for both the probability from logistic regression and score warrant discussion. First, the large sample and high prevalence would have
allowed the stepwise forward logistic regression to retain many more variables, but we terminated the selection at 13 variables for several reasons. The first reason centered on the pragmatic consideration of the time required in busy clinical practice to use the decision aid. The
second reason is concern about an overfit model, which is more likely to occur with an excessively complex derivation, regardless of the learning method [21]. Previous simulation studies
suggest that the variability of the area under the receiver operating characteristic curve with 13
variables, and a sample size of 10,000 including >30% prevalence of outcomes is less than 5%
with repeated sampling [22]. Third, at the 14th step, the model began to introduce variables
that might be more vulnerable to interobserver variability, including “active cancer” at step 14,
a variable that likely requires more inference than the retained 13 variables. A potentially
unanticipated finding is that smoking history was retained as a negative predictor of infection
—a finding that has been reported by others who have suggested that nicotine may reduce
expression of epithelial ACE2 receptor, and thus reduce SARS-CoV-2 infectivity [23–25].
Compared with persons identifying as White, Black race and Latino/Hispanic ethnicity significantly increased the probability of infection. Race-specific patterns in symptom manifestation that might alter clinical suspicion and testing threshold do not appear to explain the
differences in positive rate [26]. To our knowledge, no genetic or biologic reasons explain why
Black and Hispanic/Latino patients are more likely to have a SARS-CoV-2 infection. Instead,
the statistical weight on these variables may result from them acting as proxies for other societal factors. The association of race with positive testing may correlate with a higher likelihood
of working service-related jobs which are unable to be done from home (thereby increasing
exposure to SARS-CoV-2). In one study of a cohort of SARS-CoV-2 infected patients in Louisiana, 77% of those requiring hospitalization were Black; only 30% of the total area population
is Black [27]. However, when adjusted for socioeconomic status and pre-existing clinical
comorbidities, there was no racial difference identified in mortality [27]. Ongoing work will
report the impact of insurance status and geographic location (by four digit zip code) on
SARS-CoV-2 infection rate and severity.
The retrospective collection of data introduces the primary limitation of this work inasmuch
as the probability from logistic regression and CORC score performance, including metrics
of inter-rater reliability and operational characteristics, have not been used yet in real practice.
For example, in terms of generalizability for high throughput screening, it remains unknown
whether the temperature component, measured by an infrared thermometer, and the oxygen
saturation, measured by a portable pulse oximeter, would provide similar diagnostic accuracy.
Symptoms not recorded were assumed to be absent, which could affect score precision and
accuracy. Another limitation is the relative lack of data from most recent cases. The most recent
patient was evaluated in October and most cases came from early spring of 2020. The genotype
of the virus, as well as the phenotype of infected patients, may have changed with time, and
the effect on accuracy and imprecision are unknown. Additionally, it remains possible that
machine-based learning methods may offer a superior role, although as a preliminary step, several of the authors of this work, directly compared three derivation techniques (logistic regression, random forest and gradient boosting) to create prediction models for SARS-CoV-2 using
ED-based data. The logistic regression model had an AUC of 0.89 (95% confidence interval
[CI] = 0.84 to 0.94); the random forest method had AUC of 0.86 (95% CI = 0.79 to 0.92) and
gradient boosting had an AUC of 0.85 (95% CI = 0.79 to 0.91) [28]. It is important to note that
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all prior prediction models included use of laboratory and radiographic values. To consider the
possible benefit of machine learning, the authors reviewed the diagnostic accuracy of criteria of
20 reports to predict SARS-CoV-2 infection, including both logistic regression and machine
learning techniques [28–30]. This informal scoping review revealed that the diagnostic accuracy
of machine learning was not superior to logistic regression-based models, and therefore supported the pre-planned classical approach to model development [28].
In conclusion, we present novel criteria requiring only information that can be obtained
from the patient interview, a thermometer, and a pulse oximeter to predict the probability of
SARS-CoV-2 infection. A score of zero from the simplified COVID-19 rule-out criteria (the
CORC score) predicts a low probability of infection and a score of 5 or more predicts a high
probability of infection. If prospectively validated, we believe the CORC score will help expedite decision-making in high throughput settings.
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